CCK1R Function in Patient Leukocytes
1 other identifier
observational
112
0 countries
N/A
Brief Summary
The type 1 cholecystokinin receptor (CCK1R) is a potential target for the treatment of obesity, due to the ability of this GI hormone to elicit satiety. However, this receptor has been shown to be sensitive to the cholesterol content of the membrane in which it is expressed. Because some patients who might be candidates for the use of CCK agonists to treat their obesity and co-morbidities, the goal of this study is to determine how metabolic abnormalities might affect the responsiveness of this receptor to CCK. Because the normal site mediating CCK-stimulated satiety is on vagal afferent neurons that cannot easily be studied, we will collect buffy coat cells from a peripheral blood sample from patients involved in the Sangre Por Salud Biobank at Mountain Park Medical Center. Ex vivo, the CCK1R will be expressed on these cells and will be functionally characterized, and the cholesterol content of the cells will be assayed. These data will be correlated with the clinical, biochemical, and metabolic phenotypic data collected as part of the parent study.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P50-P75 for all trials
Started Jan 2015
Typical duration for all trials
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
January 21, 2015
CompletedPrimary Completion
Last participant's last visit for primary outcome
March 1, 2017
CompletedStudy Completion
Last participant's last visit for all outcomes
April 14, 2017
CompletedFirst Submitted
Initial submission to the registry
April 17, 2017
CompletedFirst Posted
Study publicly available on registry
April 20, 2017
CompletedApril 20, 2017
April 1, 2017
2.1 years
April 17, 2017
April 19, 2017
Conditions
Outcome Measures
Primary Outcomes (1)
Total cellular cholesterol on leukocytes collected from the subjects
The cells will be lysed by sonication; neutral sterols will be extracted, and the cholesterol will be quantified using an assay.
baseline
Study Arms (1)
Sangre Por Salud cohort members
Subjects entered in the Sangre Por Salud Biobank
Eligibility Criteria
subjects in Sangre Por Salud Biobank
You may qualify if:
- volunteers
You may not qualify if:
- Hispanic/Latino descent not pregnant, or given birth in the previous 12 months, or currently nursing not diagnosed with cancer in the past three years
Contact the study team to confirm eligibility.
Sponsors & Collaborators
- Mayo Cliniclead
Related Publications (1)
Desai AJ, Dong M, Langlais BT, Dueck AC, Miller LJ. Cholecystokinin responsiveness varies across the population dependent on metabolic phenotype. Am J Clin Nutr. 2017 Aug;106(2):447-456. doi: 10.3945/ajcn.117.156943. Epub 2017 Jun 7.
PMID: 28592602DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Laurence J Miller, MD
Mayo Clinic
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Professor of Biochemistry and Molecular Biology and Medicine and Pharmacology
Study Record Dates
First Submitted
April 17, 2017
First Posted
April 20, 2017
Study Start
January 21, 2015
Primary Completion
March 1, 2017
Study Completion
April 14, 2017
Last Updated
April 20, 2017
Record last verified: 2017-04